United States — Food and Drug Administration & Riad Sherif
3 shared events · Importance 3 · Last updated Jun 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Breakthrough Therapy designation for Privosegtor, a key regulatory milestone that accelerates its development and potential approval.
Riad Sherif: Riad Sherif, as CEO of Oculis, is the presenter of the Privosegtor program, emphasizing the company's strategic direction and the potential of the drug.
Jun 11, 2026 · 7 articles
Business
United States — Food and Drug Administration: Oculis decided not to pursue an FDA regulatory filing for OCS-01 in DME due to the trial results, meaning the drug will not be available in the United States for this indication.
Riad Sherif: As CEO of Oculis, Riad Sherif announced the disappointing Phase 3 trial results for OCS-01 and outlined the company's strategic shift to focus on other late-stage development programs.
May 29, 2026 · 18 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration granted Breakthrough Therapy designation to Oculis's Privosegtor, highlighting its potential.
Riad Sherif: Dr. Riad Sherif, CEO of Oculis, will be the presenter at the fireside chat, representing the company.
Jun 08, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how United States — Food and Drug Administration and Riad Sherif interact across events, view sentiment trends, and discover connected entities.
Open Dashboard